What Is the Best Initial Treatment for Metastatic Kidney Cancer?

The current standard treatment for advanced kidney cancer is sunitinib (Sutent), a targeted oral cancer drug in the tyrosine kinase inhibitor class. According to a standout study at the 14-16 February 2019 meeting in San Francisco, United States, the 2019 Genitourinary Cancers Symposium, immunotherapy with pembrolizumab (Keytruda) plus the tyrosine kinase inhibitor axitinib (Inlyta) significantly improved both overall and progression-free survival compared with standard sunitinib.
For a quick introduction, our infographic poster summarizing stage 4. kidney cancer treatment is useful.
Details of KEYNOTE-426
This phase-3 clinical trial provided results showing that first-line treatment with pembrolizumab plus axitinib, in clear-cell metastatic kidney cancer, prolonged overall survival and progression-free survival (PFS) compared with the current standard treatment, sunitinib.
In the study, 861 previously untreated patients with metastatic clear-cell renal cell cancer were randomly assigned to two arms. One received oral sunitinib; the other oral axitinib twice daily combined with intravenous (into a vein) pembrolizumab every 3 weeks. Treatment continued until progression or intolerable adverse effects.
Results
- Median age was 62, with % 73 men and % 27 women.
- At a mean follow-up of 12.8 months, combination therapy was associated with a % 47 reduction in mortality risk compared with sunitinib.
- The 12-month overall survival rate was % 89.9 in the combination group and % 78.3 in the sunitinib group.
- These benefits were independent of an immunotherapy biomarker , PD-L1 status.
- Median progression-free survival (time treatment controlled cancer) was 15.1 months with pembrolizumab plus axitinib and 11.1 months with sunitinib.
- Overall response rate was % 35.7 with sunitinib and % 59.3 with the combination.
- Median overall survival was 15.2 months with sunitinib but had not been reached in the combination arm because over half continued responding. Of combination recipients, % 59 remained on treatment, compared with % 43.1 receiving sunitinib.
- Among combination recipients, % 62.9 had serious (grade 3. and 4.) treatment-related adverse effects, compared with % 58.1 receiving sunitinib. Treatment was discontinued because of these effects in % 8,2 and % 10,1, respectively.
Comment
Dr. Thomas Powles, Professor of Genitourinary Oncology at Barts Cancer Institute, said, “These results are exciting.” “VEGF-targeted treatment with axitinib, when pembrolizumab is added, produces strong anticancer responses, including improved survival—and importantly, these results occur across broad patient subgroups.”
PD-L1 levels, which predict immunotherapy success in other cancers, have not been established in kidney cancer. Combining pembrolizumab with axitinib may have masked PD-L1’s predictive value. Overall, KEYNOTE-426 presents the best progression-free and overall survival data obtained in kidney cancer to date.
Sources
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.
ASCO GU 2019. J Clin Oncol 37, 2019 (suppl 7S; abstr 543)
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.